• Honoring Black History: February and Year-Round

    February 28, 2023

    With February’s Black History Month coming to a close, HDA and our members are committed to continuing to celebrate the contributions of Black and African Americans throughout history and across the country. Though the month marks a vital and designated occasion, our members and association work year-round to promote an industry culture that welcomes and celebrates the contributions of individuals from these communities and others as we strengthen the sense of belonging across the distribution sector. This blog summarizes some of the ways our sector has acknowledged Black and African American history, during this month and beyond.

  • HDA Addresses DSCSA Data-Related Challenges In Healthcare Packaging Op-Ed

    February 27, 2023

    With the end of the 10-year-implementation of the Drug Supply Chain Security Act (DSCSA) fast approaching and significant work remaining for the supply chain, HDA’s Anita Ducca, Senior Vice President, Regulatory Affairs, and Elizabeth Gallenagh, General Counsel and Senior Vice President, Supply Chain Integrity co-authored a piece for Healthcare Packaging that examines the progress toward, challenges impacting and recommendations and requirements for full implementation.

  • The Pending NDC and Barcode Rule: Manufacturers’ Perspectives

    January 23, 2023

    The FDA has proposed an amendment to its regulations to adopt a uniform, 12-digit format for the NDC. HDA’s Senior Director, Industry Relations, Tim Stearns discusses the NDC and barcode proposed amendments and analyzes manufacturers' comments.

  • Transitioning COVID-19 Product Distribution to the Commercial Market

    January 11, 2023

    Throughout the COVID-19 pandemic, the federal government has primarily coordinated response efforts with the support of the private sector to develop, produce and distribute vaccines, personal protective equipment (PPE) and therapeutics. While this public health crisis continues, government and private-sector stakeholders are already thinking about the expected transition of COVID-19 product distribution to the commercial market — which could happen as early as the first quarter of this year.

  • Chip Davis Discusses HDA’s 2023 Priorities in Annual Chain Drug Review Column

    January 09, 2023

    With the welcoming of the new year and 118th Congress, HDA’s President and CEO Chip Davis penned an overview of the association’s 2023 priorities for the January 9 issue of Chain Drug Review.

  • Reimagining the Pharmaceutical Supply Chain

    December 22, 2022

    HDA's President and CEO Chip Davis participated in a panel discussion at The Milken Institute’s 2022 Future of Health Summit entitled, “Reimagining the Pharmaceutical Supply Chain in the United States,” discussing the fundamental resilience of the pharmaceutical supply chain, while exploring the gaps and deepened growing health inequities unearthed by recent public health events.

Have a Contribution? Get In Touch

John Parker
Senior Vice President, Communications

Farah Simonett
Vice President, Editorial and Internal Communications